Indication
Severe persistent asthma
Severe persistent asthma is the most advanced baseline severity classification of asthma, a chronic inflammatory disorder of the lower respiratory tract characterized by bronchial hyperresponsiveness and variable airflow obstruction. Read more about Severe persistent asthma
223 drugs 124 manufacturers
Drugs that treat it
Common Severe persistent asthma therapies.
PREDNISONE
PREDNISONE
DEXAMETHASONE
PREDNISONE
DEXAMETHASONE
METHYLPREDNISOLONE
HYDROCORTISONE
PREDNISOLONE SODIUM PHOSPHATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSevere persistent asthma is the most advanced baseline severity classification of asthma, a chronic inflammatory disorder of the lower respiratory tract characterized by bronchial hyperresponsiveness and variable airflow obstruction.
Across pediatric and adult populations, it is clinically defined by continuous daily symptoms, frequent nighttime awakenings, extreme limitation of physical activity, and recurring exacerbations.
Pathophysiologically, persistent mucosal inflammation, goblet cell hyperplasia, and airway smooth muscle remodeling contribute to marked baseline lung impairment, typically evidenced by a forced expiratory volume in one second (FEV1) of less than 60% of predicted normal values.
- nih.gov
Severe persistent asthma is the most advanced baseline severity classification of asthma, a chronic inflammatory disorder of the lower respiratory tract characterized by bronchial hyperresponsiveness and variable airflow obstruction
- accp.com
Severe persistent asthma is the most advanced baseline severity classification of asthma, a chronic inflammatory disorder of the lower respiratory tract characterized by bronchial hyperresponsiveness and variable airflow obstruction Across pediatric and adult populations, it is clinically defined by continuous daily symptoms, frequent nighttime awakenings, extreme limitation of physical activity, and recurring exacerbations Pathophysiologically, persistent mucosal inflammation, goblet cell hyper...
- nih.gov
Across pediatric and adult populations, it is clinically defined by continuous daily symptoms, frequent nighttime awakenings, extreme limitation of physical activity, and recurring exacerbations Pathophysiologically, persistent mucosal inflammation, goblet cell hyperplasia, and airway smooth muscle remodeling contribute to marked baseline lung impairment, typically evidenced by a forced expiratory volume in one second (FEV1) of less than 60% of predicted normal values
Personalize your experience
Follow Severe persistent asthma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.